Alector, Inc. announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003. AL003 is Alector’s second clinical-stage program targeting Alzheimer’s disease and is being developed in collaboration with its partner, AbbVie. The Phase 1b portion of the INTERCEPT clinical study will assess the safety of multiple doses of AL003 in approximately 12 patients with mild to moderate Alzheimer’s disease. The study’s primary endpoints are safety and tolerability and the secondary endpoints are pharmacokinetics (PK), pharmacodynamics (PD), target engagement and target-specific biomarker changes related to AL003 in plasma and in cerebrospinal fluid (CSF) in Alzheimer’s disease patients.